Syntara (SNT) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
23 Jun, 2026Opening remarks and agenda
Meeting opened by CFO and Company Secretary, with introductions of the board and explanation of the virtual format.
Notice of meeting and proposed resolutions taken as read, with voting and Q&A procedures outlined.
Specific resolutions to be voted on
Resolution one: Approval of the issue of shares under the second tranche of a placement announced in April 2026, with voting exclusions applied.
Resolution two: Ratification of the issue of shares under the first tranche placement from April 2026 to refresh the 15% capacity, with voting exclusions applied.
Q&A with stakeholders
Opportunity for questions provided after each resolution, but no questions were raised by shareholders or proxies.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Syntara
- Phase II/2a trial of SNT-4728 targets neuroinflammation in iRBD, results due by June or 2026.SNT
Status update2 Jun 2026 - FDA backs Phase 2b amsulostat trial; funding secured for key 2026 milestones.SNT
Investor update30 Apr 2026 - FDA supports Phase 2b for amsulostat; cash runway extended after A$8m placement.SNT
Q3 202630 Apr 2026 - Amsulostat shows promising efficacy in myelofibrosis, with funding secured for pivotal trials.SNT
Investor presentation29 Apr 2026 - Net loss widened to $15.1M as revenue fell and cost reductions followed the MBU sale.SNT
H2 20247 Apr 2026 - Reduced net loss, strong cash, and key clinical milestones as a pure-play drug developer.SNT
H2 20257 Apr 2026 - Multiple late-stage assets set for key data and partnering milestones in 2024.SNT
NWR Virtual Healthcare Conference25 Mar 2026 - Net loss increased to $5.86 million as clinical programs advanced and cash reserves declined.SNT
H1 20268 Mar 2026 - Revenue up 338%, net loss halved, and strong cash position supports advancing clinical pipeline.SNT
H1 202520 Feb 2026